Opening soon. Stay in the loop

goodmorrowJoin the opening list

Tirzepatide (Zepbound), explained.

Tirzepatide (Zepbound), a weekly injection with ongoing clinical care.

Updated Clinical review pending · Educational draft

The form

Tirzepatide (Zepbound) injection

The routine

Once a week.

The evidence

Large human trials of the approved product.

Pen and vial presentations have their own instructions.

What tirzepatide is

Tirzepatide acts on two gut hormone receptors, GLP-1 and GIP, where semaglutide acts on one. Eli Lilly sells it as Zepbound for weight loss and obstructive sleep apnea, and as Mounjaro for type 2 diabetes.

What the trials showed

In SURMOUNT-1, adults on the 15 mg dose lost about 21 percent of their body weight over 72 weeks. In SURMOUNT-5, the first head-to-head trial, tirzepatide produced about 20 percent weight loss against about 14 percent for semaglutide over the same 72 weeks.

Care and medication costs

Clinical care and medication have separate self-pay costs. We confirm the exact medication price before you start. See the pricing page.

Mounjaro or Zepbound

Tirzepatide is sold as Mounjaro for type 2 diabetes and Zepbound for weight management and obstructive sleep apnea. The indication and presentation matter. Your clinician considers your diagnosis and the exact product.

How we prescribe it

  • A first visit in person with baseline labs.
  • The 2.5 mg starting dose for four weeks, then step-ups only when you're ready.
  • A monthly check-in with the same clinician.
  • Your medication and its self-pay price are confirmed separately from clinical care.

Questions people ask

Vial or pen?

Vials and pens have different presentations and instructions. Your clinician will explain the prescribed product and confirm its cost before you start.

Is Zepbound better than Wegovy?

It produced more weight loss in the head-to-head trial. That doesn't make it right for everyone. See the full comparison.

Can I get compounded tirzepatide?

Not from us. The shortage exemption ended in early 2025, and the FDA warned a major supplier in September 2026 over tirzepatide copies. More on that.

Sources

  1. Research publicationTirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) New England Journal of Medicine, 2022
  2. Research publicationTirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5) New England Journal of Medicine, 2025
  3. Manufacturer informationTirzepatide (Zepbound) prescribing information Eli Lilly, Prescribing information checked October 6, 2026

Good days ahead.

Join the opening list for appointment updates.

Join the opening list